Controlling Prostate Cancer
A new antihormone agent darolutamide (Nubeqa) provides men with nonmetastatic prostate cancer a third option to control the disease...
Progress Against Cancer
A new antihormone agent darolutamide (Nubeqa) provides men with nonmetastatic prostate cancer a third option to control the disease...
A recent study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression...
A new hormone therapy is the first treatment to be approved because it was found to markedly delay the...
Study: Urban native populations may have decreased survival following invasive prostate and breast cancer. Urban American Indians and Alaskan...
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts....
Men with prostate cancer were less likely to die of the disease if they exercised. Maintaining an exercise routine,...
Eating red meat, processed meat, and a high fat-diet after a prostate cancer diagnosis may affect a man’s risk...
Men with metastatic, castrate-resistant prostate cancer with mutations in genes linked to DNA repair responded to targeted therapy. Data...
A new study finds that physical activity lowers the likelihood of death in men with localized prostate cancer. Physical...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 44,000 members worldwide drive progress against cancer.
Donate Today